Creating new cancer drugs using peptide drug conjugates for triple negative breast cancer
Development of peptide drug conjugates for cancer therapy
This study is working on new treatments for triple negative breast cancer by creating special drug combinations that can deliver chemotherapy directly to the tumor, making it more effective and helping patients feel better.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Molecular Theranostics, LLC NIH-funded |
| Lab location | 1 site (Beachwood, United States) |
| Project ID | NIH-10760236 on NIH RePORTER |
What this research studies
This research focuses on developing innovative peptide drug conjugates specifically designed to treat triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer that often does not respond to standard therapies. The approach involves creating targeted delivery systems that can effectively transport chemotherapy drugs directly to the tumor site, overcoming barriers that typically hinder drug delivery in solid tumors. By utilizing previously developed peptide agents that target specific proteins in the tumor environment, the research aims to enhance the efficacy of cancer treatments and improve patient outcomes.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have limited treatment options.
Not a fit: Patients with other types of breast cancer or those who have already responded well to existing therapies may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with triple negative breast cancer, potentially improving survival rates and quality of life.
How similar studies have performed: Previous research has shown promise in using targeted drug delivery systems for cancer treatment, indicating that this approach could be effective.
Where this research is happening
Beachwood, United States
- Molecular Theranostics, LLC — Beachwood, United States (Active)
Researchers
- Principal investigator: Hall, Ryan Christopher — Molecular Theranostics, LLC
- Study coordinator: Hall, Ryan Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.